Cite
HARVARD Citation
Pivot, X. et al. (2018). A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. European journal of cancer. pp. 19-27. [Online].